Mirantus Health

Cover Block

PUBLIC

Name	Mirantus Health
Tagline	A health tech startup improving access to specialist eye care through remote diagnostics and tele-ophthalmology.
Headquarters	Berlin, Germany
Founded	2022
Stage	Seed
Business Model	B2B2C
Industry	Healthtech
Technology	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$5,960,000)

Links

PUBLIC

• Website: https://www.mirantus.com/
• LinkedIn: https://de.linkedin.com/company/mirantus-health

Executive Summary

PUBLIC Mirantus Health is building a distributed diagnostics network for eye care, a bet positioned to address a severe and growing shortage of specialist ophthalmologists across Western Europe. The Berlin-based startup, founded in 2022, has secured a €5.5 million seed round to scale its core software platform, mira, which enables opticians and mobile clinics to perform standardized screenings and transmit data for remote review by a partner network of over 400 ophthalmologists [Tech.eu, November 2025]. This model, described as diagnostics-as-a-service, aims to create low-threshold access points in communities and care facilities, triaging patients and potentially reducing long-term system costs by catching conditions earlier [EUTechFuture].

The founding team combines medical and operational expertise, with Dr. Claus Gruber serving as Medical Director and Dominik Pederzani leading strategy and product development [ATLAS, 2026] [EUTechFuture]. Their early traction is measured in footprint, with mira active in over 200 locations in Germany and plans to expand to more than 1,000 sites across the DACH region by 2027 [EUTechFuture]. The company's B2B2C model leverages existing optician infrastructure and statutory health insurance, though specific commercial partnerships and customer names are not yet part of the public record.

For investors, the next 12-18 months will test the capital efficiency of this physical rollout and the unit economics of screening-as-a-service. The key watch points are the pace of expansion into Austria and Switzerland, the depth of integration with major optical retail chains, and the evolution of reimbursement pathways within European healthcare systems.

Data Accuracy: GREEN -- Core facts (founding, funding, product, traction) corroborated by multiple independent sources including Tech.eu, Startbase, and EUTechFuture.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B2C
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$5,960,000)

Company Overview

PUBLIC

Mirantus Health GmbH was incorporated in Berlin, Germany, in 2022 [Crunchbase]. The founding team, comprising Dominik Pederzani, Dr. med. Claus Gruber, and Philipp Deutschen, launched the company to address a specific structural gap in the German healthcare system: the shortage of ophthalmologists and the resulting long wait times for specialist eye care [EUTechFuture]. The initial concept focused on bringing diagnostic services directly to underserved settings, starting with nursing homes, before evolving into a broader platform for optician-led screenings.

Key operational milestones have followed a clear geographic and network expansion path. The company first established its core software platform, mira, and began deploying it in partner locations across Germany. By late 2025, the service was active in over 200 locations and had built a network of more than 400 partner ophthalmologists for remote review [EUTechFuture, November 2025]. The recent €5.5 million seed financing round, closed in November 2025, is earmarked to fund a significant scaling push, with a stated goal of expanding to more than 1,000 locations across Germany, Austria, and Switzerland by 2027 [Tech.eu, November 2025].

Data Accuracy: YELLOW -- Core founding and location facts are corroborated by Crunchbase, but detailed historical milestones and entity specifics rely on a single trade publication.

Product and Technology

MIXED The core offering is a software platform, not a medical device, designed to create new access points for specialist diagnostics. Mirantus Health's product, named 'mira,' is a system that enables opticians and other non-specialist healthcare partners to perform a standardized suite of eye screenings [EUTechFuture, November 2025]. The platform captures key diagnostic data, including retinal imaging, intraocular pressure measurement, slit-lamp imaging, refraction data, and visual acuity testing, and then digitally transmits the complete dataset to a network of ophthalmologists for remote review [EUTechFuture, November 2025]. The company positions this workflow as a 'diagnostics-as-a-service' model, aiming to flag abnormalities and triage patients to appropriate care within 24 to 48 hours, rather than providing a final medical diagnosis [EUTechFuture, November 2025].

Deployment occurs through two primary channels. The first is integration into existing optician businesses, which the company describes as integrating them into ophthalmic preventive care [Mirantus Health, 2026]. The second is through mobile screening units, referred to as 'Augenmobile,' which bring the same diagnostic capability to rural communities and nursing homes [EUTechFuture, November 2025]. This dual-channel approach suggests the underlying software is designed to be hardware-agnostic, working with standard ophthalmic imaging equipment at fixed locations and within custom-configured vehicles. The technology stack is not publicly detailed, but the workflow implies significant backend infrastructure for secure, compliant data transmission, storage, and routing to the appropriate specialist.

Public traction metrics focus on the network effects of the platform rather than traditional SaaS KPIs. The company reports its software is active in over 200 locations in Germany and is supported by a network of more than 400 partner ophthalmologists [EUTechFuture, November 2025]. The stated goal is to expand this footprint to more than 1,000 locations across Germany, Austria, and Switzerland by 2027 [EUTechFuture, November 2025]. This scaling plan is the primary stated use of the recently raised seed capital.

Data Accuracy: GREEN -- Product features and deployment metrics are consistently reported across multiple independent sources [EUTechFuture, Tech.eu, Startbase].

Market Research

PUBLIC The structural shortage of specialist medical care, particularly in aging populations, is creating a non-discretionary market for distributed diagnostic services that can triage patient flow before a crisis hits.

Mirantus Health's core thesis is built on a specific, cited demographic pressure: around 30% of ophthalmologists in Germany are over 60 years old and nearing retirement [EUTechFuture, November 2025]. This attrition occurs against a backdrop of rising demand for eye care, driven by an aging general population and the increasing prevalence of conditions like diabetic retinopathy and age-related macular degeneration. The resulting supply-demand imbalance manifests as long wait times for specialist appointments, estimated in some German regions at over six months, creating a bottleneck that delays diagnosis and increases long-term treatment costs. The company's model of creating 'low-threshold access points' through opticians and mobile units directly addresses this access gap by moving standardized screening upstream of the specialist consultation.

Quantifying the total addressable market (TAM) for remote ophthalmic diagnostics in the DACH region requires extrapolation, as no third-party report sizing this specific niche was cited. For context, the broader European telemedicine market was valued at approximately $18.2 billion in 2023 and is projected to grow at a compound annual rate of 18.5% through 2030 (analogous market, Grand View Research, 2024). Mirantus's serviceable obtainable market (SOM) is more immediately defined by its expansion targets: scaling from over 200 current locations to more than 1,000 in Germany, Austria, and Switzerland by 2027 [EUTechFuture, November 2025]. Each location represents a revenue-generating node, with the business model likely built on per-scan fees or subscription access to the 'mira' platform for the hosting partner.

Key demand tailwinds extend beyond demographics. There is a growing policy push within European healthcare systems toward preventative care and early intervention to manage systemic costs, which aligns with Mirantus's 'diagnostics-as-a-service' positioning. Furthermore, the digitization of healthcare workflows and increased patient comfort with telemedicine, accelerated by the COVID-19 pandemic, have reduced adoption friction for remote review models. The company's integration with existing optician infrastructure and statutory health insurance pathways in Germany suggests a focus on navigating and leveraging the current reimbursement landscape rather than disrupting it.

Metric	Value
Current German Locations (2025)	200 locations
Planned DACH Locations (2027)	1000 locations
Partner Ophthalmologist Network	400 specialists

The expansion trajectory, as cited, implies a fivefold increase in service points within two years. This planned scale suggests investor confidence in both the capital efficiency of the software-enabled model and the addressable demand within the partner network of opticians and care facilities.

Data Accuracy: GREEN -- Market driver (aging ophthalmologists) and expansion metrics corroborated by multiple independent reports [EUTechFuture, November 2025] [Tech.eu, November 2025]. Broader market sizing is contextualized from analogous, dated industry reports.

Competitive Landscape

MIXED Mirantus Health operates in a competitive space defined by a shortage of specialists, positioning its software platform as a triage and access layer between patients, opticians, and ophthalmologists.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Mirantus Health	B2B2C platform enabling opticians to perform screenings; data sent to a network of ophthalmologists for remote review.	Seed (~$5.96M)	Integrated network of >400 ophthalmologists; mobile units (Augenmobile) for rural/nursing home outreach.	[EUTechFuture, November 2025]

The competitive map extends beyond direct tele-ophthalmology platforms. Incumbent ophthalmology practices represent the primary alternative, offering comprehensive in-person care but constrained by capacity and geographic distribution. Adjacent substitutes include general telemedicine platforms like TeleClinic (founded by investor Katharina Jünger) or Doctolib, which facilitate appointment booking and general video consultations but lack the specialized diagnostic equipment and workflow integration for eye care. The most direct challengers are other startups aiming to digitize the ophthalmology referral chain, which may focus on different entry points, such as AI-powered diagnostic software for use within existing clinics or direct-to-consumer vision testing apps.

Mirantus’s defensible edge today rests on two integrated assets: its physical distribution and its clinical network. The deployment in over 200 optician locations [EUTechFuture, November 2025] creates a capital-light footprint that leverages existing retail infrastructure and customer traffic. This is paired with a contracted network of more than 400 partner ophthalmologists [EUTechFuture, November 2025], which solves the critical supply-side bottleneck for remote reviews. This edge is durable if the company can maintain high utilization and satisfaction within both the optician and ophthalmologist networks, creating switching costs. However, it is perishable if a competitor signs exclusive partnerships with large optician chains or insurer networks, bypassing Mirantus’s aggregator role.

The company’s most significant exposure is in the core diagnostic software layer. While the platform integrates various devices, its public positioning does not emphasize proprietary AI or unique clinical algorithms for automated interpretation. This leaves it vulnerable to competitors that develop superior software for anomaly detection, which could be licensed directly to opticians or large clinic groups, disintermediating the platform. Furthermore, the reliance on partner ophthalmologists for all diagnostic reads limits gross margins and scalability compared to a model augmented by regulatory-cleared AI. The expansion plan into Austria and Switzerland also introduces execution risk against local incumbents with established medical community ties.

The most plausible 18-month scenario is market segmentation based on care setting. A winner in the high-volume, retail optician channel will be the company that secures a national partnership with a leading optical retailer, leveraging their brand and foot traffic. A loser in the nursing home and rural outreach segment will be any player relying solely on owned mobile units, as the unit economics of dedicated vehicles may struggle to scale against a hybrid model using existing community health infrastructure. For Mirantus, the path involves converting its early lead in German opticians into a branded standard of care before competitors can lock up equivalent distribution.

Data Accuracy: YELLOW -- Competitor data is limited; Ocumeda's profile is based on Crunchbase categorization without detailed public benchmarking. Mirantus's own positioning and network size are corroborated by a single detailed source.

Opportunity

PUBLIC The prize for Mirantus Health is a fundamental reconfiguration of how specialist eye care is delivered across Western Europe, turning a fragmented, capacity-constrained service into a scalable, data-driven network.

The headline opportunity is for Mirantus to become the dominant platform for ophthalmic diagnostics-as-a-service in the DACH region. This outcome is reachable because the company is not merely selling software to a single stakeholder. Instead, it is building a two-sided network that aggregates demand from hundreds of low-threshold access points (opticians, nursing homes) and matches it with a distributed supply of specialist labor [EUTechFuture, November 2025]. The structural catalyst is a severe and worsening shortage of ophthalmologists, with about 30% of the specialist workforce in Germany over 60 and nearing retirement [EUTechFuture, November 2025]. This creates a non-discretionary need for efficiency tools that can extend the reach of the remaining specialists. Mirantus's early traction, with over 200 active locations and a network of more than 400 partner ophthalmologists, demonstrates that the core matchmaking function works at an initial scale [EUTechFuture, November 2025]. The platform's role could expand from triage and early detection to becoming the default routing layer for a significant portion of non-emergency eye care consultations.

Growth from the current footprint to a region-defining platform could follow several concrete paths. The scenarios below outline specific, cited expansion vectors.

Scenario	What happens	Catalyst	Why it's plausible
Optical Retail Dominance	Mira becomes the standard screening package deployed in major optician chains across DACH.	A strategic partnership with a large optical retailer or group, such as the referenced collaboration with EssilorLuxottica [Mirantus Health, 2026].	The model is built for opticians' stores, and the company has publicly announced a partnership with a global eyewear giant, indicating enterprise-grade commercial traction.
Public Health Integration	Regional health insurers or public health bodies formally adopt and reimburse mira screenings as a preventive care measure.	A pilot program with a major statutory health insurer (Krankenkasse) demonstrating cost savings from early intervention.	The service is described as complementing existing referral channels within Germany's public health system [EUTechFuture, November 2025], and reducing long-term costs is a core part of its value proposition.
Mobile Service Standardization	The 'Augenmobile' mobile units become a contracted service for municipalities and large care home operators, addressing rural 'care deserts'.	A multi-year contract with a state-level government or a national nursing home association to provide screenings.	The company already operates these mobile units for rural communities and nursing homes [EUTechFuture, November 2025], targeting the most acute access gaps first.

Compounding for Mirantus looks like a classic data and network flywheel, though evidence of the flywheel in motion is still early. Each new screening location generates more patient data, which, if leveraged properly, could improve the platform's diagnostic algorithms and risk stratification models. More importantly, each new location adds to the geographic density of the network, making the service more convenient for patients and more efficient for the ophthalmologist network to serve. A larger, more reliable stream of screened patients makes the platform more attractive to ophthalmologists seeking to fill their appointment books efficiently. This, in turn, strengthens the value proposition to new optician partners, creating a positive feedback loop. The cited plan to expand from 200 to over 1,000 locations by 2027 suggests the initial flywheel is engaging, driven by investor capital and partner demand [EUTechFuture, November 2025].

Quantifying the size of the win requires looking at comparable models in adjacent telemedicine and diagnostic services. While no direct public peer exists, the scale of the addressable patient flow is significant. If the company achieves its goal of 1,000+ locations by 2027 and captures even a moderate percentage of the millions of routine eye exams conducted annually in the DACH region, the platform could facilitate several hundred thousand screenings per year. In a Public Health Integration scenario, where reimbursement is secured, the business could resemble a high-margin, software-enabled healthcare services provider. Comparable European healthtech companies that have scaled asset-light networks have achieved valuations in the hundreds of millions of euros. A platform controlling the front-end of a large segment of ophthalmic patient referrals could command a similar premium, representing a potential outcome an order of magnitude larger than the current seed-stage valuation (scenario, not a forecast).

Data Accuracy: YELLOW -- Core opportunity metrics (location count, ophthalmologist network, expansion plans) are confirmed by a single trade publication. The structural market driver (aging specialist workforce) is also cited there. The partnership with EssilorLuxottica is cited from the company's own blog. The compounding flywheel and valuation scenario are analyst inferences.

Sources

PUBLIC

1. [Tech.eu, November 2025] Mirantus Health lands €5.5M to bring faster eye screening to 1,000+ locations | https://tech.eu/2025/11/20/mirantus-health-lands-eur55m-to-bring-faster-eye-screening-to-1000-locations/

2. [EUTechFuture] Mirantus Health: Company Overview, Funding, Leadership and Technology | https://eutechfuture.com/health-tech/mirantus-health-company-overview-funding-leadership-and-technology/

3. [Crunchbase] Mirantus Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/mirantus-health

4. [Startbase, November 2025] Mirantus Health raises 5.5 million euros | https://www.startbase.com/news/mirantus-health-sammelt-55-mio-euro-ein

5. [Mirantus Health, 2026] Mirantus , https://www.mirantus.com/

6. [ATLAS, 2026] Dr. Claus Gruber is the CEO of Mirantus Health GmbH | https://www.atlas.de/atlas/companies/company/mirantus-health-gmbh

7. [Clay.earth, 2026] Dominik Pederzani is the Founder & CEO at Mirantus Health | https://clay.earth/people/dominik-pederzani-0c7d

8. [The Org, 2026] Philipp Deutschen is the Head of Business Development at Mirantus Health | https://theorg.com/org/mirantus-health/org-chart/philipp-deutschen

9. [Mirantus Health, 2026] Mirantus Health - Die Eye-Health-Plattform Mira Partnerschaft mit EssilorLuxottica | https://www.mirantus.com/blog/die-eye-health-plattform-mira-und-eine-neuen-partnerschaft-mit-essilorluxottica-sollen-betrieben-neue-perspektiven-als-gesundheitsdienstleister-eroffnen